I want to know if Pluvicto is reimbursed in greece?

I can help, but reimbursement can change and depends on the exact cancer indication (and sometimes the hospital/region).

In general: Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been introduced in the EU, and Greece has implemented reimbursement for certain eligible patients, typically in line with EMA-approved indications and the corresponding Greek health authority/cancer reimbursement rules.

To give you the correct “yes/no” for Greece right now, I need one detail:
1) Which indication are you asking about? (e.g., PSMA-positive metastatic castration-resistant prostate cancer after taxane chemotherapy or another line), and
2) Are you asking about public reimbursement (EOPYY/public system) or private/assistance programs?

If you tell me the indication (or the exact clinical description), I can look up/guide you to the most likely Greek reimbursement status and where to verify it (typically via EOPYY or the Greek positive reimbursement list / oncology drug programs, depending on the year).